Please login to the form below

Not currently logged in
Email:
Password:

J&J falling drug sales offset by medical devices

US firm playing a game of brinkmanship as deadline for improved offer for Guidant approaches

Johnson & Johnson (J&J) has seen US sales of prescription drugs fall, despite recording a 79 per cent increase in profit for the fourth quarter.

The US healthcare firm, which is embroiled in a bidding war with Boston Scientific for medical device maker Guidant, had net income of $2.18bn, or 73 cents a share, compared with $1.22bn, or 41 cents a share, a year earlier.

ìThe year 2005 was a solid one for Johnson & Johnson, despite significant challenges,î said chairman and CEO William Weldon. ìWe delivered excellent full-year earnings results, while continuing to make the major investments that will fuel future growth.î

Sales of US prescription drugs in 2005 fell 10.2 per cent to $3.57bn, down from $3.98bn the previous year, weaker on increased generic competition to pain patch, Duragesic, and safety concerns over heart-failure drug, Natrecor and anaemia drug Procrit.

However, international sales of prescription drugs actually rose 2.6 per cent to $1.9bn from $1.86bn the previous year.

Growth in J&J's medical devices and diagnostics unit offset the weaker demand for prescription drugs, with worldwide sales rising 13.1 per cent to $19.1bn in 2005, helped by strong sales of the Cypher stent.

At the time of writing, Weldon had until midnight tonight (Tuesday) to respond to Boston Scientific's offer to pay $27bn, or $80 a share in cash and shares, for Guidant, which trumped J&J's $24.2bn offer. On Friday, proxy advisers at Institutional Shareholder Services recommended Guidant investors reject the J&J bid.

The Guidant board had earlier accepted the J&J bid over Boston Scientific's even though it was smaller, on the basis that had cleared an antitrust review and would therefore be completed much more quickly.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics